Myopia News Briefs

CooperVision’s MiSight Prescriber Study Highlights Confidence in Myopia Control

June 9, 2022

SAN RAMON, Calif. — In a study of more than 100 ECPs who have prescribed CooperVision’s MiSight 1 day contact lenses, the company has learned that practitioners have embraced the product for their myopic patients. Findings span confidence in the lens, duty to care, and the relationship between the ECPs and patients and parents.

The study found that 97% of ECPs are confident that fitting the innovative contact lenses to age-appropriate* patients with myopia will have a positive impact on patients’ long-term vision health,†1 which is a key consideration in myopia management.

An encouraging sign of positive change, 96% of these ECPs believe that offering MiSight 1 day to their age-appropriate patients with myopia demonstrates that they are a leader in providing the best vision care, and 97% agree that more ECPs should offer myopia management options.#1

Of surveyed ECPs, 87% further report that myopia management is the standard of care in their practice.¶1 This significant majority aligns with the World Council of Optometry resolution advising all optometrists to incorporate a standard of care for myopia management in their practices.

Though myopia management can represent a significant lifestyle commitment and financial investment for parents of children with myopia, the research indicated that 70% of parents purchase MiSight 1 day after it is prescribed to their age-appropriate children.  The parent-ECP relationship also benefits: 87% of ECPs shared that by prescribing MiSight 1 day to their age-appropriate patients with myopia, they strengthened their relationship with those families as a result.§1

“MiSight 1 day is the only FDA-approved* soft contact lenses to date proven to slow myopia progression in children, aged 8-12 at the initiation of treatment. Its value is even more resounding with this new data,” said Justin Kwan, OD, Senior Manager of Myopia Management for CooperVision. “Myopia control takes teamwork and commitment from ECPs, parents, and children. The ECP confidence and conviction that shines through this data leave no doubt that MiSight 1 day is enabling and supporting that success.”

References

1 CVI data on file 2022. U.S. CooperVision online survey: ECP MiSight Perspectives; n=101 ECPs that prescribe MiSight 1 day.

2 Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8)556-567.

* Indications for Use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

77% strongly agree, 20% somewhat agree that prescribing MiSight 1 day contact lenses to age-appropriate patients with myopia will have a positive impact on their patient’s long-term vision health.

‡ 66% strongly agree, 30% somewhat agree that that offering MiSight 1 day to their age-appropriate patients with myopia demonstrates that they are a leader in offering the best vision care to their pediatric patients

# 75% strongly agree, 22% somewhat agree that more ECPs should be involved in practicing myopia management options with their myopic pediatric patients to take care of their long-term vision health.

 ¶ 56% strongly agree, 31% somewhat agree that myopia management is the standard of care in their practice.

§ 50% strongly agree, 37% somewhat agree that prescribing MiSight 1 day to their age-appropriate patients with myopia has strengthened their relationship with those families.

± Compared to a single vision 1 day lens over a 3 year period.

To Top